Orap Forte (Pimozide)

Orap Forte (pimozide) acts on dopaminergic pathways that are implicated in several neuro‑behavioral disorders.

• Tourette syndrome: reduces the frequency and severity of motor and vocal tics.
• Chronic schizophrenia: helps control persistent psychotic symptoms when other agents are insufficient.
• Huntington’s disease chorea: diminishes involuntary movements and improves functional ability.
• Severe behavioral disturbances in autism spectrum disorder: lessens aggression and self‑injurious behavior.
• Psychotic relapse prevention: maintains stability after acute treatment phases.

• Pimozide blocks dopamine D2 receptors in the central nervous system, decreasing dopaminergic neurotransmission that underlies psychotic and motor‑tics manifestations. It also exhibits antagonism at serotonin 5‑HT2 and alpha‑adrenergic receptors, contributing to its broader neuro‑behavioral effects. The combined receptor blockade modulates neuronal firing patterns, helping to stabilize mood and reduce involuntary movements.

Adverse reactions to pimozide are reported across a spectrum of frequency and severity.

Common Side Effects

• Sedation or drowsiness
• Dry mouth
• Constipation
• Blurred vision
• Weight gain
• Orthostatic hypotension

Serious or Rare Side Effects

• Extrapyramidal symptoms (e.g., dystonia, parkinsonism)
• QT‑interval prolongation leading to cardiac arrhythmias
• Neuroleptic malignant syndrome
• Severe depression or suicidal thoughts
• Agranulocytosis
• Hepatotoxicity

When prescribing pimozide, clinicians should evaluate patient history and monitor for specific safety concerns.

• Cardiac assessment: obtain baseline ECG and monitor QT interval regularly.
• Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcemia before initiation.
• Drug‑interaction review: avoid concurrent use with strong CYP3A4 inhibitors.
• Liver function: assess hepatic enzymes and adjust dose if impairment is present.
• Pregnancy and lactation: weigh risks versus benefits; use only if clearly needed.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Pimozide has a notable potential for pharmacokinetic and pharmacodynamic interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause dangerous plasma level spikes.
• Other QT‑prolonging agents (e.g., quinidine, sotalol): increase risk of cardiac arrhythmias.
• Antifungal azoles: elevate pimozide concentrations and heighten toxicity.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): require dose adjustment and ECG monitoring.
• Central nervous system depressants (e.g., benzodiazepines, opioids): may enhance sedation.
• Antihistamines with anticholinergic properties: can worsen dry‑mouth and constipation.